271 related articles for article (PubMed ID: 24867966)
1. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
[TBL] [Abstract][Full Text] [Related]
2. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
3. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
4. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.
Rajotte D; Tremblay S; Pelletier A; Salois P; Bourgon L; Coulombe R; Mason S; Lamorte L; Sturino CF; Bethell R
Antimicrob Agents Chemother; 2013 Jun; 57(6):2712-8. PubMed ID: 23545531
[TBL] [Abstract][Full Text] [Related]
6. Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.
Xu HT; Colby-Germinario SP; Quashie PK; Bethell R; Wainberg MA
Antimicrob Agents Chemother; 2015; 59(6):3189-96. PubMed ID: 25779585
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
8. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
[TBL] [Abstract][Full Text] [Related]
9. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z; Herman BD; Sheen CW; Zelina S; Moore KL; Tachedjian G; Nissley DV; Sluis-Cremer N
J Virol; 2009 Apr; 83(8):3826-33. PubMed ID: 19193782
[TBL] [Abstract][Full Text] [Related]
10. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Andreatta KN; Goodman DD; Miller MD; White KL
Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
[TBL] [Abstract][Full Text] [Related]
11. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
12. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204
[TBL] [Abstract][Full Text] [Related]
13. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.
Deval J; White KL; Miller MD; Parkin NT; Courcambeck J; Halfon P; Selmi B; Boretto J; Canard B
J Biol Chem; 2004 Jan; 279(1):509-16. PubMed ID: 14551187
[TBL] [Abstract][Full Text] [Related]
16. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
McCormick AL; Parry CM; Crombe A; Goodall RL; Gupta RK; Kaleebu P; Kityo C; Chirara M; Towers GJ; Pillay D
Antimicrob Agents Chemother; 2011 Apr; 55(4):1806-9. PubMed ID: 21282419
[TBL] [Abstract][Full Text] [Related]
17. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Stone C; Ait-Khaled M; Craig C; Griffin P; Tisdale M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
[TBL] [Abstract][Full Text] [Related]
20. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
